Aug 23, 2023
siRNAgen Therapeutics Announces the Appointment of Renowned Scientific and
siRNAgen Therapeutics, a leading biotech in the RNAi therapeutics space, is pleased to announce the expansion of its advisory board with the inclusion of distinguished scientific and strategic experts.
Sep 29, 2022
siRNAgen Awarded Johnson & Johnson Innovation Seoul Innovation QuickFire Challenge
Johnson & Johnson Innovation LLC and Janssen Korea Ltd. Announce siRNAgen as an Awardee of the Seoul Innovation QuickFire Challenge: Scientific Advancements of Tomorrow in Collaboration with Seoul Metropolitan Government and Korea Health Industry Development Institute
Sep 15, 2022
siRNAgen Therapeutics joins Endless Frontier Labs
siRNAgen Therapeutics has been selected to join the Endless Frontier Labs 2022-2023 cohort. This year’s 75 ground-breaking companies were selected amongst a competitive pool of over 1,000 applicants. siRNAgen will be joining as one of 26 that have been selected for the Life Sciences Track.